Migraine is to be added to NHS England’s Pharmacy First service from autumn 2026, giving people with low frequency episodic migraine in England another route to assessment, advice and appropriate treatment through participating community pharmacies.
The move represents a further expansion of the role of community pharmacy within NHS care and highlights how healthcare pathways are continuing to evolve beyond traditional GP-led models.
Expanding access through community pharmacy
Launched in January 2024, Pharmacy First enables people to seek advice and treatment for a defined range of common conditions directly from participating community pharmacies.
Depending on the condition and individual circumstances, pharmacists can provide self-care advice, recommend or supply appropriate medicines, prescribe where within their scope, or refer someone to another NHS service when further assessment or treatment is required.
The addition of migraine extends this model into an area where timely assessment and appropriate treatment can be particularly important.
The initial rollout will be gradual, beginning with a limited number of pharmacies before wider implementation.
What does this mean for migraine care?
For people experiencing migraine, the change provides an additional route into NHS care, potentially reducing reliance on GP appointments for appropriate cases and enabling support to be accessed closer to home.
The Migraine Trust’s recent Cost of Waiting report highlighted challenges around access to primary care, with 29% of respondents reporting that they had been unable to access a GP appointment when they needed one.
Pharmacy First does not replace the role of GPs or specialist services. Rather, it adds another point within the care pathway, with pharmacists able to provide advice and treatment where appropriate and refer patients onwards where further investigation or specialist input is required.
That distinction is important. Effective expansion of community pharmacy services depends not only on access, but on clear clinical pathways, appropriate prescribing and referral arrangements, and robust governance.
A changing healthcare pathway
The inclusion of migraine in Pharmacy First is another example of how responsibility for elements of healthcare delivery is increasingly being distributed across different parts of the NHS.
For pharmaceutical and healthcare organisations, developments such as this can have implications beyond the immediate point of care. Changes to treatment pathways can influence how medicines are accessed, prescribed and monitored, as well as the information and support healthcare professionals need to use them appropriately.
As Pharmacy First develops, ensuring that expanded access is supported by appropriate clinical governance and clearly defined pathways will be an important part of its implementation.
For companies developing or supplying medicines and healthcare products, understanding how changes in NHS policy and service delivery affect the regulatory and clinical environment remains an important part of market planning.
At Woodley BioReg, we support pharmaceutical, biotech, medical device and diagnostics companies with regulatory and quality requirements across the product lifecycle, helping organisations understand and respond to a changing healthcare environment.
Back to News + Insights